182 related articles for article (PubMed ID: 3443146)
21. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
22. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
23. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
24. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.
Miners JO; Wing LM; Birkett DJ
Aust N Z J Med; 1985 Jun; 15(3):348-9. PubMed ID: 3864428
[TBL] [Abstract][Full Text] [Related]
25. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
Gross AS; Mikus G; Fischer C; Hertrampf R; Gundert-Remy U; Eichelbaum M
Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
[TBL] [Abstract][Full Text] [Related]
26. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS; Tucker GT; Woods HF
Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
[TBL] [Abstract][Full Text] [Related]
27. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
28. Debrisoquine oxidation in an Australian population.
Peart GF; Boutagy J; Shenfield GM
Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
[TBL] [Abstract][Full Text] [Related]
29. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Lennard MS; Silas JH; Freestone S; Trevethick J
Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
[TBL] [Abstract][Full Text] [Related]
30. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
Lennard MS; McGourty JC; Silas JH
Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891
[TBL] [Abstract][Full Text] [Related]
31. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
Broly F; Vandamme N; Libersa C; Lhermitte M
Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
[TBL] [Abstract][Full Text] [Related]
32. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Eichelbaum M; Bertilsson L; Säwe J
Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
[TBL] [Abstract][Full Text] [Related]
33. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
Wanwimolruk S; Chalcroft S
Br J Clin Pharmacol; 1991 Nov; 32(5):617-20. PubMed ID: 1954076
[TBL] [Abstract][Full Text] [Related]
34. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
35. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
36. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
Horai Y; Taga J; Ishizaki T; Ishikawa K
Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
[TBL] [Abstract][Full Text] [Related]
37. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
38. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
[TBL] [Abstract][Full Text] [Related]
40. The metabolism of [14C]-debrisoquine in man.
Idle JR; Mahgoub A; Angelo MM; Dring LG; Lancaster R; Smith RL
Br J Clin Pharmacol; 1979 Mar; 7(3):257-66. PubMed ID: 371651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
